MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia

Conditions

• Accelerated Phase Chronic Myelogenous Leukemia
• Acute Leukemias of Ambiguous Lineage
• Acute Myeloid Leukemia/Transient Myeloproliferative Disorder
• Acute Undifferentiated Leukemia
• Aggressive NK-cell Leukemia
• Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative
• Blastic Phase Chronic Myelogenous Leukemia
• Blastic Plasmacytoid Dendritic Cell Neoplasm
• Childhood Burkitt Lymphoma
• Childhood Chronic Myelogenous Leukemia
• Childhood Diffuse Large Cell Lymphoma
• Childhood Grade III Lymphomatoid Granulomatosis
• Childhood Immunoblastic Large Cell Lymphoma
• Childhood Nasal Type Extranodal NK/T-cell Lymphoma
• Chronic Eosinophilic Leukemia
• Chronic Myelomonocytic Leukemia
• Chronic Neutrophilic Leukemia
• Chronic Phase Chronic Myelogenous Leukemia
• Intraocular Lymphoma
• Juvenile Myelomonocytic Leukemia
• Mast Cell Leukemia
• Myeloid/NK-cell Acute Leukemia
• Noncutaneous Extranodal Lymphoma
• Post-transplant Lymphoproliferative Disorder
• Primary Central Nervous System Hodgkin Lymphoma
• Primary Central Nervous System Non-Hodgkin Lymphoma
• Progressive Hairy Cell Leukemia, Initial Treatment
• Prolymphocytic Leukemia
• Recurrent Childhood Acute Lymphoblastic Leukemia
• Recurrent Childhood Acute Myeloid Leukemia
• Recurrent Childhood Anaplastic Large Cell Lymphoma
• Recurrent Childhood Grade III Lymphomatoid Granulomatosis
• Recurrent Childhood Large Cell Lymphoma
• Recurrent Childhood Lymphoblastic Lymphoma
• Recurrent Childhood Small Noncleaved Cell Lymphoma
• Recurrent Grade 1 Follicular Lymphoma
• Recurrent Grade 2 Follicular Lymphoma
• Recurrent Grade 3 Follicular Lymphoma
• Recurrent Mantle Cell Lymphoma
• Recurrent Marginal Zone Lymphoma
• Recurrent Mycosis Fungoides/Sezary Syndrome
• Recurrent Small Lymphocytic Lymphoma
• Recurrent/Refractory Childhood Hodgkin Lymphoma
• Refractory Chronic Lymphocytic Leukemia
• Refractory Hairy Cell Leukemia
• Relapsing Chronic Myelogenous Leukemia
• Secondary Acute Myeloid Leukemia
• Small Intestine Lymphoma
• Splenic Marginal Zone Lymphoma
• Unspecified Childhood Solid Tumor, Protocol Specific
• Waldenström Macroglobulinemia

Interventions

• DRUG: Akt inhibitor MK2206
• OTHER: diagnostic laboratory biomarker analysis
• OTHER: pharmacological study

Sponsor

National Cancer Institute (NCI)